1-20 of 167
Massimo Cristofanilli
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A009: Mutant KRAS in Circulating Tumor DNA Assessed by Digit Droplet PCR as a Biomarker in Pancreatic Cancer in Patients Treated with Neoadjuvant Chemotherapy

Dominic Vitello, Dhavan Shah, Amy Wells, Larissa Masnyk, Madison Cox, Lauren Janczewski, John Abad, Kevin Dawravoo, Arlene D'Souza, Grace Suh, Robert Bayer, Massimo Cristofanilli, David Bentrem, Yingzhe Liu, Hui Zhang, Lucas Santana-Santos, Lawrence Jennings, Qiang Zhang, Akhil Chawla
Journal: Cancer Research
Cancer Res (2024) 84 (17_Supplement_2): A009.
https://doi.org/10.1158/1538-7445.PANCREATIC24-A009
Published: 15 September 2024
View article titled, Abstract A009: Mutant KRAS in Circulating Tumor DNA Assessed by Digit Droplet PCR as a Biomarker in Pancreatic Cancer in Patients Treated with Neoadjuvant Chemotherapy
Journal Articles

Abstract PO5-08-11: Genetic Landscape of Early Breast Cancer in an Ashkenazi Jewish Cohort

Laura Munoz Arcos, Eleonora Nicolò, Maira Pires, Letizia Pontolillo, Leticia Varella, Tessa Cigler, Eleni Andreopolu, Anne Moore, Ashley Schreier, Carlos Munoz-Zuluaga, Lisa Newman, Georgia Syrnioti, Massimo Cristofanilli
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO5-08-11.
https://doi.org/10.1158/1538-7445.SABCS23-PO5-08-11
Published: 02 May 2024
View article titled, Abstract PO5-08-11: Genetic Landscape of Early Breast Cancer in an Ashkenazi Jewish Cohort
Journal Articles

Abstract PO3-14-12: SIRT3 as a new potential predictive biomarker for response to CDK4/6 inhibition in ER+/HER2- metastatic breast cancer patients

Maroua Manai, Ghada Sahraoui, Raoudha Doghri, Lorenzo Gerratana, Paolo D’Amico, Youbin Zhang, Jeannine Donahue, Ami Shah, Carolina Reduzzi, Wenan Qiang, Massimo Cristofanilli
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO3-14-12.
https://doi.org/10.1158/1538-7445.SABCS23-PO3-14-12
Published: 02 May 2024
View article titled, Abstract PO3-14-12: SIRT3 as a new potential predictive biomarker for response to CDK4/6 inhibition in ER+/HER2- metastatic breast cancer patients
Journal Articles

Abstract PO3-14-11: Association between BRCA alterations detected by circulating tumor DNA and germline mutations in breast cancer patients: a retrospective mono-institutional analysis

Letizia Pontolillo, Eleonora Nicolò, Laura Munoz Arcos, Carolina Reduzzi, Mara Serena Serafini, Amanda Kaylan Strickland, Nadia Bayou, Jeannine Donahue, Elisabetta Molteni, Lorenzo Gerratana, Diana Giannarelli, Eleni Andreopoulou, Emilio Bria, Massimo Cristofanilli
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO3-14-11.
https://doi.org/10.1158/1538-7445.SABCS23-PO3-14-11
Published: 02 May 2024
View article titled, Abstract PO3-14-11: Association between BRCA alterations detected by circulating tumor DNA and germline mutations in breast cancer patients: a retrospective mono-institutional analysis
Journal Articles

Abstract PO5-15-02: Integration of synonymous mutations and variants of unknown significance for basal and longitudinal characterization of metastatic breast cancer by circulating tumor DNA

Elisabetta Molteni, Carolina Reduzzi, Andrew Davis, Lorenzo Foffano, Arielle Medford, Katherine Clifton, Whitney L. Hensing, Marko Velimirovic, Ami N. Shah, Laura Munoz Arcos, Charles S. Dai, Jennifer C. Keenan, Elyssa Denault, William Gradishar, Giuseppe Damante, Amir Behdad, Lorenzo Gerratana, Fabio Puglisi, Cynthia Ma, Aditya Bardia, Massimo Cristofanilli
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO5-15-02.
https://doi.org/10.1158/1538-7445.SABCS23-PO5-15-02
Published: 02 May 2024
View article titled, Abstract PO5-15-02: Integration of synonymous mutations and variants of unknown significance for basal and longitudinal characterization of metastatic breast cancer by circulating tumor DNA
Journal Articles

Abstract PO4-18-02: Real-world (RW) utilization and patient outcomes across three CDK4/6 inhibitors in metastatic breast cancer (mBC)

Caroline Weipert, Seth Wander, Andrew Davis, Leslie Bucheit, Jayati Saha, Jiemin Liao, Nicole Zhang, Daniel Stover, Aditya Bardia, Massimo Cristofanilli
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO4-18-02.
https://doi.org/10.1158/1538-7445.SABCS23-PO4-18-02
Published: 02 May 2024
View article titled, Abstract PO4-18-02: Real-world (RW) utilization and patient outcomes across three CDK4/6 inhibitors in metastatic breast cancer (mBC)
Journal Articles

Abstract PO1-01-09: Neoadjuvant endocrine therapy and avelumab with or without palbociclib in stage II/III endocrine receptor-positive breast cancer: the ImmunoADAPT trial

Phaedon Zavras, Ruizhe Chen, Hanfei Qi, Mary Kate Jones, Ann Folmer, Hayden Chae, Allen Khodab, Ashley Cimino-Mathews, Lisa Jacobs, Lisa Mullen, Christie Hiton, Ahmed Elkhanany, Katia Khoury, Massimo Cristofanilli, Elizabeth Jaffee, Vered Stearns, Cesar Santa-Maria
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO1-01-09.
https://doi.org/10.1158/1538-7445.SABCS23-PO1-01-09
Published: 02 May 2024
View article titled, Abstract PO1-01-09: Neoadjuvant endocrine therapy and avelumab with or without palbociclib in stage II/III endocrine receptor-positive breast cancer: the ImmunoADAPT trial
Journal Articles

Abstract PO1-18-12: Trial in progress: Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating locally advanced or ER+/HER2- metastatic breast cancer with an ESR1 mutation

Matthew Goetz, Seth Wander, Thomas Bachelot, Gerald Batist, Javier Cortés, Massimo Cristofanilli, Giuseppe Curigliano, Alexandre de Nonneville, Einav Nili-Gal Yam, Komal Jhaveri, Cynthia Ma, Heather Parsons, Hope Rugo, Sarah Sammons, Daniel Stover, Chris Twelves, Aditya Bardia, Paul V. Plourde, David J Portman, Senthil Damodaran
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO1-18-12.
https://doi.org/10.1158/1538-7445.SABCS23-PO1-18-12
Published: 02 May 2024
View article titled, Abstract PO1-18-12: Trial in progress: Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating locally advanced or ER+/HER2- metastatic breast cancer with an ESR1 mutation
Journal Articles

Abstract PO1-06-04: Immune checkpoint inhibitors for triple-negative inflammatory breast cancer (INCORPORATE): an international multicenter retrospective analysis

Carmine Valenza, Dario Trapani, Paola Zagami, Gabriele Antonarelli, Luca Boscolo Bielo, Eleonora Nicolò, Joana Mourato Ribeiro, Lorenzo Guidi, Carolina REDUZZI, Martina Spotti, Elisabetta Munzone, Javier Cortés, Barbara Pistilli, Sara Tolaney, Naoto Ueno, Rachel Layman, Massimo Cristofanilli, Lisa Carey, Filipa Lynce, Wendy Woodward, Giuseppe Curigliano
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO1-06-04.
https://doi.org/10.1158/1538-7445.SABCS23-PO1-06-04
Published: 02 May 2024
View article titled, Abstract PO1-06-04: Immune checkpoint inhibitors for triple-negative inflammatory breast cancer (INCORPORATE): an international multicenter retrospective analysis
Journal Articles

Abstract PS12-02: Exploration of ctDNA Dynamics in the PACE Trial: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for HR+/HER2- Metastatic Breast Cancer

Rinath Jeselsohn, Jingxin Fu, Yue Ren, Reshma Mahtani, Cynthia Ma, Angela DeMichele, Massimo Cristofanilli, Jane Meisel, Kathy Miller, Yara Abdou, Elizabeth Riley, Rubina Qamar, Priyanka Sharma, Sonya Reid, Naomi Ko, Yuan Liu, Harold Burstein, Michelle DeMeo, Sara Tolaney, Erica Mayer
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PS12-02.
https://doi.org/10.1158/1538-7445.SABCS23-PS12-02
Published: 02 May 2024
View article titled, Abstract PS12-02: Exploration of ctDNA Dynamics in the PACE Trial: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for HR+/HER2- Metastatic Breast Cancer
Journal Articles

Abstract PS06-03: Differences in ctDNA genomic profiles and outcomes of Black and White patients with metastatic breast cancer: results from a large multicenter consortium

Emily Podany, Lorenzo Foffano, Lorenzo Gerratana, Arielle Medford, Katherine Clifton, Whitney Hensing, Renee Morecroft, Marko Velimirovic, Ami Shah, Carolina REDUZZI, Laura Munoz Arcos, Charles S. Dai, Jennifer Keenan, Elyssa Denault, Foluso Ademuyiwa, Fabio Puglisi, Cynthia Ma, Aditya Bardia, Massimo Cristofanilli, Andrew Davis
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PS06-03.
https://doi.org/10.1158/1538-7445.SABCS23-PS06-03
Published: 02 May 2024
View article titled, Abstract PS06-03: Differences in ctDNA genomic profiles and outcomes of Black and White patients with metastatic breast cancer: results from a large multicenter consortium
Journal Articles

Abstract PO2-20-02: A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1)

Sara Hurvitz, Fabrice André, Massimo Cristofanilli, Giuseppe Curigliano, Antonio Giordano, Hyo Han, Miguel Martín, Barbara Pistilli, Hope Rugo, Robert Wesolowski, Igor Gorbatchevsky, Sibylle Loibl
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO2-20-02.
https://doi.org/10.1158/1538-7445.SABCS23-PO2-20-02
Published: 02 May 2024
View article titled, Abstract PO2-20-02: A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1)
Journal Articles

Abstract PO4-15-06: Genomic landscape characterization after exposure to cyclin dependent kinase 4/6 inhibitors: a retrospective multi-institutional consortium analysis

Letizia Pontolillo, Carolina Reduzzi, Andrew Davis, Lorenzo Gerratana, Arielle Medford, Katherine Clifton, Whitney L. Hensing, Marko Velimirovic, Ami N. Shah, Jeannine Donahue, Laura Munoz Arcos, Charles S. Dai, Jennifer Keenan, Amir Behdad, William Gradishar, Emilio Bria, Cynthia Ma, Aditya Bardia, Massimo Cristofanilli
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO4-15-06.
https://doi.org/10.1158/1538-7445.SABCS23-PO4-15-06
Published: 02 May 2024
View article titled, Abstract PO4-15-06: Genomic landscape characterization after exposure to cyclin dependent kinase 4/6 inhibitors: a retrospective multi-institutional consortium analysis
Journal Articles

Abstract PO4-15-04: Differential genomic profiling of progesterone receptor (PR) negative, estrogen receptor (ER) positive HER2-negative metastatic breast cancer (MBC) through circulating tumor DNA

Lorenzo Gerratana, Andrew Davis, Arielle Medford, Carolina Reduzzi, Katherine Clifton, Emily Podany, Whitney Hensing, Marko Velimirovic, Ami N. Shah, Lorenzo Foffano, Laura Munoz Arcos, Eleonora Nicolò, Charles S. Dai, Jennifer Keenan, Amir Behdad, Seth Wander, William Gradishar, Cynthia Ma, Fabio Puglisi, Aditya Bardia, Massimo Cristofanilli
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO4-15-04.
https://doi.org/10.1158/1538-7445.SABCS23-PO4-15-04
Published: 02 May 2024
View article titled, Abstract PO4-15-04: Differential genomic profiling of progesterone receptor (PR) negative, estrogen receptor (ER) positive HER2-negative metastatic breast cancer (MBC) through circulating tumor DNA
Journal Articles

Abstract PO2-14-09: Baseline genomic alterations and the activity of lasofoxifene (LAS) plus abemaciclib (Abema) in patients with ER+/HER2- metastatic breast cancer (mBC): the ELAINE 2 study

Senthil Damodaran, Massimo Cristofanilli, Matthew Goetz, Ciara O'Sullivan, Gary Riordan, Hope Rugo, Daniel Stover, Seth Wander, Dominic Carroll, Paul V. Plourde, David J Portman, Einav Nili-Gal Yam
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO2-14-09.
https://doi.org/10.1158/1538-7445.SABCS23-PO2-14-09
Published: 02 May 2024
View article titled, Abstract PO2-14-09: Baseline genomic alterations and the activity of lasofoxifene (LAS) plus abemaciclib (Abema) in patients with ER+/HER2- metastatic breast cancer (mBC): the ELAINE 2 study
Journal Articles

Abstract PO4-19-06: Phase II study of a PARP inhibitor, talazoparib, in HER2- metastatic breast cancer with a somatic BRCA1/2 mutation present in cell-free DNA or tumor tissue genotyping

Neelima Vidula, Senthil Damodaran, Manali Bhave, Hope Rugo, Ami N. Shah, Erica Blouch, Nathan Royce Ruffle-Deignan, Ogadinma Ogbenna, Lisa E. Flaum, Massimo Cristofanilli, Joseph Sparano, Harry Ostrer, Vandana Abramson, Nora Horick, Aditya Bardia
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO4-19-06.
https://doi.org/10.1158/1538-7445.SABCS23-PO4-19-06
Published: 02 May 2024
View article titled, Abstract PO4-19-06: Phase II study of a PARP inhibitor, talazoparib, in HER2- metastatic breast cancer with a somatic BRCA1/2 mutation present in cell-free DNA or tumor tissue genotyping
Journal Articles

Abstract PO3-06-05: Association of tumor-derived extracellular vesicles with circulating tumor DNA alterations in metastatic breast cancer patients: exploring differences in inflammatory breast cancer

Eleonora Nicolò, Lorenzo Gerratana, Lorenzo Foffano, Laura Munoz Arcos, Mara Serena Serafini, Maroua Manai, Letizia Pontolillo, Nadia Bayou, Elisabetta Molteni, Amanda Kaylan Strickland, Youbin Zhang, Paolo D’Amico, Andrew Davis, Jeannine Donahue, Huiping liu, William Gradishar, Ami Shah, Giuseppe Curigliano, Carolina Reduzzi, Massimo Cristofanilli
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO3-06-05.
https://doi.org/10.1158/1538-7445.SABCS23-PO3-06-05
Published: 02 May 2024
View article titled, Abstract PO3-06-05: Association of tumor-derived extracellular vesicles with circulating tumor DNA alterations in metastatic breast cancer patients: exploring differences in inflammatory breast cancer
Journal Articles

Abstract PO5-25-04: Predictive value of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in patients with triple negative breast cancer treated with pembrolizumab

Ashley Schreier, Roberta Zappasodi, Inna Serganova, Laura Munoz Arcos, Xi Kathy Zhou, Massimo Cristofanilli, Eleni Andreopolu
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO5-25-04.
https://doi.org/10.1158/1538-7445.SABCS23-PO5-25-04
Published: 02 May 2024
View article titled, Abstract PO5-25-04: Predictive value of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in patients with triple negative breast cancer treated with pembrolizumab
Journal Articles

Abstract 3707: Characterization of estrogen receptor expression on CTCs during CDK4/6i treatment in HR+/HER2- metastatic breast cancer: Results from the PACE phase II study

Mara Serena Serafini, Carolina Reduzzi, Lorenzo Gerratana, Rinath Jeselsohn, Reshma L. Mahtani, Cynthia X. Ma, Angela DeMichele, Jane Lowe Meisel, Kathy D. Miller, Yara Abdou, Elizabeth C. Riley, Rubina Qamar, Priyanka Sharma, Sonya Reid, Harold J. Burstein, Sara M. Tolaney, Michelle K. DeMeo, Yuan Liu, Eric Gauthier, Yue Ren, Meredith M. Regan, Huiping Liu, Erica L. Mayer, Massimo Cristofanilli
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3707.
https://doi.org/10.1158/1538-7445.AM2024-3707
Published: 22 March 2024
View article titled, Abstract 3707: Characterization of estrogen receptor expression on CTCs during CDK4/6i treatment in HR+/HER2- metastatic breast cancer: Results from the PACE phase II study
Journal Articles

Abstract 3693: Molecular and functional characterization of circulating CK+/CD45+ cells in breast cancer

Carolina Reduzzi, Eleonora Nicolo, Lauren L. Ozimski, Marco Silvestri, Lorenzo Gerratana, Mara S. Serafini, Elisabetta Molteni, Nadia Bayou, Amanda K. Strickland, Huiping Liu, Vera Cappelletti, Nicola Aceto, Massimo Cristofanilli
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3693.
https://doi.org/10.1158/1538-7445.AM2024-3693
Published: 22 March 2024
View article titled, Abstract 3693: Molecular and functional characterization of circulating CK+/CD45+ cells in breast cancer